Nosca-Méréprine (Noscapine Hydrochloride Monohydrate)

Nosca-Méréprine is used to alleviate cough by acting on the central cough reflex pathway.

• Acute cough: reduces the frequency and intensity of coughing episodes.
• Chronic cough: provides symptomatic relief for persistent cough lasting more than eight weeks.
• Cough associated with respiratory infections: helps control irritation‑driven cough during viral or bacterial upper‑respiratory tract infections.

• Noscapine Hydrochloride exerts its antitussive effect primarily through central suppression of the cough reflex. Although the exact molecular target is not fully defined, the compound is thought to modulate neuronal activity in the medullary cough center, decreasing the sensitivity of cough‑triggering pathways and thereby reducing the urge to cough.

Nosca-Méréprine may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Dizziness: transient light‑headedness.
• Drowsiness: mild sedation, especially at higher doses.
• Gastrointestinal discomfort: abdominal cramping or mild diarrhea.
• Headache: occasional tension‑type headache.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Allergic reactions: rash, itching, or swelling of the face and throat.
• Anaphylaxis: rare but potentially life‑threatening hypersensitivity.
• Hepatic dysfunction: elevated liver enzymes in susceptible individuals.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hematologic abnormalities: unexplained bruising or bleeding.
• Respiratory depression: extremely rare, usually with concomitant CNS depressants.

When prescribing Nosca-Méréprine, clinicians should consider several safety aspects.

• Assess renal function: adjust use in patients with severe renal impairment.
• Monitor hepatic status: avoid in individuals with known liver disease.
• Avoid in known hypersensitivity: discontinue if allergic signs appear.
• Caution with CNS depressants: increased risk of sedation or respiratory depression.
• Use in pregnancy only if clearly needed: limited data on fetal safety.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nosca-Méréprine can interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid)

• Concurrent use with other central nervous system depressants (e.g., opioids, benzodiazepines): may potentiate sedation and respiratory depression.
• Combination with other antitussive agents (e.g., dextromethorphan): risk of additive central effects.

Moderate Interactions (Monitor Closely)

• CYP450 substrates: noscapine may modestly inhibit certain enzymes, potentially altering plasma levels of drugs such as warfarin.
• Antihistamines: may increase drowsiness.
• Alcohol: can enhance central nervous system depression.